Biosimilars

Taylor Dispersion Analysis is an ultra-low volume, microcapillary flow technique for sizing and stability of biomolecules in complex solutions, and offers advantages for orthogonal and complementary biophysical characterization measurements.

In-depth analysis of original and new candidate drugs for biosimilars is easier than ever before…

Sitting Down With… Carsten Brockmeyer, CEO, Formycon, Germany.

The first US biosimilar - Zarxio from Sandoz - has been cleared for market. But the judges say it wasn't an easy decision.

Taylor Dispersion measurements are used to monitor self-association and oligomeric state in a variety of buffer conditions.

The rise of biosimilars is great news for overburdened healthcare systems, but it’s a very different proposition to a simple generic.

In the midst of wrangles over biosimilars naming and interchangeability, let’s not forget the key benefit...

A US government study reports progress – but also highlights shortfalls

Regulators and manufacturers are readying for the opening of the US market, but legal wrangles continue to block the way.

We speak to Professor Begoña Calvo to find out more about her research into pharmaco vigilance for biosimilars.